摘要
近年来,我国前列腺癌的发病率呈逐年上升趋势,且多数患者诊断时已为晚期,虽然雄激素剥夺治疗(ADT)能使多数患者的病情在短时间内得到缓解,但几乎所有的患者最终均发展为去势抵抗性前列腺癌(CRPC)。此类患者预后极差,治疗极为棘手,急需探索新的治疗策略。精准医学的出现与癌症基因组高通量测序的兴起使CRPC患者的分子分型成为可能。就前列腺癌的分子分型、临床精准诊治研究进展进行综述,以期探索新的CRPC诊疗之路。
The incidence of prostate cancer in China has been increasing in recent years,and most cases have already reached the advanced stage when the diagnosis is confirmed. Although many patients are initially sensitive to androgen deprivation therapy( ADT) and experience temporary tumor regression,nearly all will develop castration-resistant prostate cancer( CRPC),which is difficult to cure and thus has poor prognosis. Newtherapies for CRPC remains an urgent need. The emergence of precision medicine and high-throughput sequencing of cancer genomes makes molecular typing of CRPC patients possible. This article reviews the molecular typing of prostate cancer and development of precision medicine in the treatment of CRPC.
作者
王海涛
WANG Haitao(Department of Oncology,Second Hospital of Tianjin Medical University,Tianjin Institute of Urology,Tianjin 300211,China)
出处
《山东大学学报（医学版）》
CAS
北大核心
2019年第1期30-35,共6页
Journal of Shandong University:Health Sciences
基金
国家自然科学基金(81572543)
天津市科技计划项目(17ZXMFSY00040)
关键词
去势抵抗性前列腺癌
精准医学
高通量测序
分子靶向治疗
Castration-resistant prostate cancer
Precision medicine
High-throughput sequencing
Molecular targeted therapy
